BioRestorative Therapies (BRTX) Change in Receivables (2015 - 2025)
BioRestorative Therapies' (BRTX) quarterly Change in Receivables came in at $2100.0 in Q4 2025, down 91.03% YoY from $23400.0 in Q4 2024, and up 231.25% on a QoQ basis from -$1600.0 in Q3 2025.
BioRestorative Therapies (BRTX) Change in Receivables (2015 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 11 years of Change in Receivables data on file, last reported at $2100.0 in Q4 2025.
- Quarterly Change in Receivables fell 91.03% year-over-year to $2100.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$172900.0 (down 202.25% YoY) and the FY2025 annual result came in at -$172900.0, down 202.25% from the prior year.
- Change in Receivables rose to $2100.0 in Q4 2025, from -$1600.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $137600.0 in Q3 2024 to a low of -$163400.0 in Q1 2025.
- A 5-year average of -$617.65 and a median of -$1600.0 in 2025 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables jumped 1000.0% — and 2025, when it sank 1140.76%.
- Tracing BRTX's Change in Receivables over 5 years: stood at -$3000.0 in 2021, then sank by 866.67% to -$29000.0 in 2022, then jumped by 31.03% to -$20000.0 in 2023, then surged by 217.0% to $23400.0 in 2024, then tumbled by 91.03% to $2100.0 in 2025.
- The last three Change in Receivables figures came in at $2100.0 (Q4 2025), -$1600.0 (Q3 2025), and -$10000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 | 2,100.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,100.00 |
| Dec 31, 2025 | 2,100.00 |
| Sep 30, 2025 | -1,600.00 |
| Sep 30, 2025 | -1,600.00 |
| Jun 30, 2025 | -10,000.00 |
| Jun 30, 2025 | -10,000.00 |
| Mar 31, 2025 | -163,400.00 |
| Mar 31, 2025 | -163,400.00 |
| Dec 31, 2024 | 23,400.00 |
| Dec 31, 2024 | 23,400.00 |
| Sep 30, 2024 | 137,600.00 |
| Sep 30, 2024 | 137,600.00 |
| Jun 30, 2024 | -7,600.00 |
| Jun 30, 2024 | -7,600.00 |
| Mar 31, 2024 | 15,700.00 |
| Mar 31, 2024 | 15,700.00 |
| Dec 31, 2023 | -20,000.00 |
| Dec 31, 2023 | -20,000.00 |
| Sep 30, 2023 | 14,300.00 |
| Sep 30, 2023 | 14,300.00 |